文献速递类风湿关节炎

商业保险新发类风湿关节炎患者糖皮质激素处方模式及提供者层面差异:回顾性队列研究

Patterns of glucocorticoid prescribing and provider-level variation in a commercially insured incident rheumatoid arthritis population: A retrospective cohort study.
PubMed 文献 · Semin Arthritis Rheum · 2019-09-07

该回顾性队列研究利用美国Optum行政数据库,纳入9221例2010-2014年新诊断的18-65岁RA患者,评估诊断前3个月至诊断后12个月糖皮质激素处方模式。72.8%患者至少配药一次,31.3%患者累积供应≥3个月,诊断后29.2%患者10-12个月仍使用激素;风湿科医生处方最多且个体间差异大。

要点

  • 72.8%新诊断RA患者在研究期间至少配药一次糖皮质激素。
  • 31.3%患者累积供应≥3个月,中位日剂量10 mg/day、供应189天。
  • 诊断后29.2%患者在10-12个月仍接受糖皮质激素处方。

核心结论

  • 商业保险新发RA患者中,长期接受≥10 mg/day泼尼松等效剂量数月者常见,且29.2%患者在诊断后一年仍持续使用。
  • 糖皮质激素处方在不同风湿科医生间差异广泛。

研究设计与样本

  • 回顾性队列研究,使用美国全国Optum行政数据库。
  • 纳入9221例2010-2014年诊断的18-65岁新发RA成人患者。
  • 评估诊断前3个月至诊断后12个月的糖皮质激素配药情况,按日历季度和处方者专科分层。

主要发现

  • 6717例(72.8%)患者在研究期间至少配药一次糖皮质激素。
  • 2890例(31.3%)患者累积供应≥3个月,中位(IQR)日剂量10(6.6)mg/day,供应天数189(143)天。
  • 52.6%患者在诊断后1-3个月接受糖皮质激素,29.2%在诊断后10-12个月接受糖皮质激素。
  • 诊断后使用糖皮质激素者中,季度中位日剂量和供应天数持续≥10 mg/day和≥30天。
  • 风湿科医生处方的季度中位日剂量和供应天数分别为10 mg/day和43-60天,个体风湿科医生处方在各季度差异广泛。

临床怎么用

  • 风湿免疫科医生应关注新诊断RA患者糖皮质激素的长期使用模式,尤其是诊断后一年仍持续处方的患者。
  • 需识别导致风湿科医生间糖皮质激素处方差异的提供者因素,并评估其对健康结局的影响。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

OBJECTIVE: Glucocorticoids are common in RA management despite an unfavorable, exposure-dependent risk profile impacted by patient and provider-level factors. Existing work describing glucocorticoid use in RA is not generalizable and does not adequately examine provider factors. We aim to describe how providers prescribe glucocorticoids to commercially insured, newly diagnosed RA patients in the United States. METHODS: This was a retrospective cohort study which used the national Optum© administrative database. We identified 9221 adults ages 18-65 with RA diagnosed 2010-2014. We assessed glucocorticoid dispensing 3 months pre-diagnosis through 12months post-diagnosis ("study period"), cumulatively stratified by calendar quarter and prescriber specialty (rheumatologist, primary care, other). We examined prescribing variation among individual rheumatologists by dividing quarterly distribution of per-patient dose and days' supply into quartiles. RESULTS: 6717 (72.8%) patients filled ≥1 glucocorticoid prescription during the study period. 2890 (31.3%) patients received ≥3 months' supply, with median (IQR) daily dose 10 (6.6) mg/day and days' supply 189 (143) days. 52.6% of patients received glucocorticoids 1-3 months post-diagnosis; 29.2% received glucocorticoids 10-12 months post-diagnosis. Among glucocorticoid users post-diagnosis, quarterly median daily dose and days' supply were consistently ≥10 mg/day and ≥30 days, respectively. Rheumatologists prescribed most glucocorticoids, with median per-quarter daily dose and days' supply 10 mg/day and 43-60 days. Individual rheumatologists' prescribing varied widely across all quarters. CONCLUSION: Among commercially insured incident RA patients, receipt of ≥10 mg/day prednisone equivalent for months is common, typically prescribed by rheumatologists, and persists a year post-diagnosis in 29.2% of patients. Glucocorticoid prescribing varies widely across rheumatologists. Further work is warranted to identify provider factors explaining variation in glucocorticoid prescribing, and assess how these affect health outcomes.

来源:Semin Arthritis Rheum,查看原文。版权归原作者所有。

引用

  1. Wallace BI, Lin P, Kamdar N, et al. Patterns of glucocorticoid prescribing and provider-level variation in a commercially insured incident rheumatoid arthritis population: A retrospective cohort study. Semin Arthritis Rheum. 2019. PMID: 31522762. doi:10.1016/j.semarthrit.2019.09.002

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。